Patricia Isaacs, MD
Family Medicine · Clarksville, INNPI 1790916690
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,021 of the $46,866 with a category attached, or 70.5%. 33 manufacturers reported payments, led by AbbVie at 52.9% of the total. Reporting peaked in 2022 at $19,988 and has fallen 95.0% since, to $1,003 in 2025. Among family medicine clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 561 payments — averaging $83.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$25K
- Novo Nordisk$14K
- Amgen$2K
- AstraZeneca$2K
- Pfizer$439
- Amarin Pharma, Inc.$347
- plus $4K from 27 others
What the payments were for
- Speaking & faculty fees$33,02170%
- Travel & lodging$1,3513%
- Food & beverage$12,35726%
- Education$1370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 177 | $24,785 |
| Novo Nordisk | 49 | $13,662 |
| Amgen(2 entities) | 41 | $1,802 |
| AstraZeneca | 25 | $1,681 |
| Pfizer | 33 | $439 |
| Amarin Pharma, Inc. | 14 | $347 |
| Lilly USA, LLC | 14 | $316 |
| Bayer | 7 | $295 |
| Biohaven Pharmaceuticals, Inc. | 20 | $294 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $284 |
| Boehringer Ingelheim | 25 | $283 |
| Johnson & Johnson(2 entities) | 22 | $279 |
| Sunovion Pharmaceuticals Inc. | 17 | $244 |
| Abbott | 6 | $228 |
| Exact Sciences | 2 | $218 |
| E.r. Squibb & Sons, L.L.C. | 9 | $195 |
| Biohaven Pharmaceutical Holding Company Ltd. | 32 | $175 |
| Sumitomo Pharma America, Inc. | 9 | $133 |
| Astellas Pharma US Inc | 2 | $127 |
| Urovant Sciences Inc | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| Radius Health, Inc. | 1 | $123 |
| Dexcom, Inc. | 1 | $119 |
| Sanofi-aventis U.S. LLC | 2 | $111 |
| Merck | 14 | $111 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $107 |
| Alkermes, Inc. | 1 | $100 |
| Daiichi Sankyo Inc. | 3 | $53 |
| Tactile Systems Technology Inc | 1 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $25 |
| Genentech USA, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
| Dynavax Technologies Corporation | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$46,866 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 122 | $108,260 |
| ProliaDenosumab | 45 | $78,478 |
| MounjaroTirzepatide | 66 | $75,426 |
| TrulicityDulaglutide | 38 | $50,563 |
| JardianceEmpagliflozin | 30 | $32,197 |
| XareltoRivaroxaban | 24 | $26,612 |
| FarxigaDapagliflozin Propanediol | 30 | $25,379 |
| TradjentaLinagliptin | 23 | $24,164 |
| OzempicSemaglutide | 15 | $22,110 |
| GemtesaVibegron | 24 | $21,166 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $20,830 |
| Spiriva RespimatTiotropium Bromide | 27 | $19,998 |
| Tresiba Flextouch U-200Insulin Degludec | 22 | $18,113 |
| Repatha SureclickEvolocumab | 16 | $14,958 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $14,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $316 | $125,990104 claims |
| PfizerEliquis | $439 | $108,260122 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat, Trijardy Xr | $283 | $97,217111 claims |
| AmgenProlia | $1,802 | $78,47845 claims |
| AstraZenecaFarxiga, Symbicort | $1,681 | $32,64548 claims |
| Johnson & JohnsonXarelto | $279 | $26,61224 claims |
| Novo NordiskOzempic | $13,662 | $22,11015 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $133 | $21,16624 claims |
| AbbVieLinzess, Synthroid | $24,785 | $14,48156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Clarksville
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.